Literature DB >> 16199434

Lysophosphatidic acid enhances interleukin-13 gene expression and promoter activity in T cells.

Joshua Rubenfeld1, Jia Guo, Nitat Sookrung, Rongbing Chen, Wanpen Chaicumpa, Vincenzo Casolaro, Yutong Zhao, Viswanathan Natarajan, Steve Georas.   

Abstract

Lysophosphatidic acid (LPA) is a membrane-derived lysophospholipid with wide-ranging effects on multiple lung cells including airway epithelial and smooth muscle cells. LPA can augment migration and cytokine synthesis in lymphocytes, but its potential effects on Th2 cytokines have not been well studied. We examined the effects of physiological concentrations of LPA on IL-13 gene expression in human T cells. The Jurkat T cell line and human peripheral blood CD4+ T cells were incubated with LPA alone or with 1) pharmacological agonists of different signaling pathways, or 2) antibodies directed against the T cell receptor complex and costimulatory molecules. Luciferase-based reporter constructs driven by different lengths of the human IL-13 promoter were transfected by electroporation in Jurkat cells treated with and without LPA. The effects of LPA on IL-13 mRNA stability were examined using actinomycin D to halt ongoing transcription. Expression of mRNA encoding LPA2 and LPP-1 increased with T cell activation. LPA augmented IL-13 secretion under conditions of submaximal T cell activation. This was observed using pharmacological agonists activating intracellular calcium-, PKC-, and cAMP-dependent signaling pathways, as well as antibodies directed against CD3 and CD28. LPA only slightly prolonged IL-13 mRNA half-life in submaximally stimulated Jurkat cells. In contrast, LPA significantly enhanced transcriptional activation of the IL-13 promoter via regulatory elements contained within proximal 312 bp. The effects of LPA on IL-13 promoter activation appeared to be distinct from those mediated by GATA-3. LPA can augment IL-13 gene expression in T cells, especially under conditions of submaximal activation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16199434     DOI: 10.1152/ajplung.00473.2004

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  29 in total

1.  Lysophosphatidic acid effects on atherosclerosis and thrombosis.

Authors:  Mei-Zhen Cui
Journal:  Clin Lipidol       Date:  2011-08

Review 2.  Regulation of mammalian physiology, development, and disease by the sphingosine 1-phosphate and lysophosphatidic acid receptors.

Authors:  Victoria A Blaho; Timothy Hla
Journal:  Chem Rev       Date:  2011-09-22       Impact factor: 60.622

Review 3.  International Union of Basic and Clinical Pharmacology. LXXVIII. Lysophospholipid receptor nomenclature.

Authors:  Jerold Chun; Timothy Hla; Kevin R Lynch; Sarah Spiegel; Wouter H Moolenaar
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

4.  Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression.

Authors:  Shannon K Oda; Pamela Strauch; Yuko Fujiwara; Amin Al-Shami; Tamas Oravecz; Gabor Tigyi; Roberta Pelanda; Raul M Torres
Journal:  Cancer Immunol Res       Date:  2013-10       Impact factor: 11.151

5.  Lpa2 is a negative regulator of both dendritic cell activation and murine models of allergic lung inflammation.

Authors:  Jason Emo; Nida Meednu; Timothy J Chapman; Fariba Rezaee; Marlene Balys; Troy Randall; Tirumalai Rangasamy; Steve N Georas
Journal:  J Immunol       Date:  2012-03-16       Impact factor: 5.422

Review 6.  The roles of autotaxin/lysophosphatidic acid in immune regulation and asthma.

Authors:  Seung-Jae Kim; Hyung-Geun Moon; Gye Young Park
Journal:  Biochim Biophys Acta Mol Cell Biol Lipids       Date:  2020-01-29       Impact factor: 4.698

Review 7.  Lysophosphatidic acid signaling in airway epithelium: role in airway inflammation and remodeling.

Authors:  Yutong Zhao; Viswanathan Natarajan
Journal:  Cell Signal       Date:  2008-10-26       Impact factor: 4.315

Review 8.  Lysophosphatidic acid and autotaxin: emerging roles in innate and adaptive immunity.

Authors:  Steve N Georas
Journal:  Immunol Res       Date:  2009-01-30       Impact factor: 2.829

Review 9.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

10.  Lysophosphatidic acid induces interleukin-13 (IL-13) receptor alpha2 expression and inhibits IL-13 signaling in primary human bronchial epithelial cells.

Authors:  Yutong Zhao; Donghong He; Jing Zhao; Lixin Wang; Alan R Leff; Ernst Wm Spannhake; Steve Georas; Viswanathan Natarajan
Journal:  J Biol Chem       Date:  2007-02-06       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.